Although multiple retrospective studies have shown a correlation between urinary CXCL10 and kidney allograft rejection, the randomized controlled trial failed to demonstrate a benefit of urinary CXCL10 monitoring on one-year outcomes [12]. Here, CXCL10 is linked to urogenital neoplasm.